Beyond CRISPR: The precision tool that could finally cure HIV
Biopharma Dealmaker’s latest feature highlights PROVIREX’s innovative approach to HIV treatment using precision gene-editing technology. Unlike conventional CRISPR methods, their designer recombinase (Brec1) targets and removes the integrated HIV provirus with remarkable accuracy, effectively addressing HIV’s primary persistence mechanism. View the full article here.
This article was produced by PROVIREX’s. If you’re interested in partnering with us, contact us to find out more about our sponsorship opportunities. By collaborating through Nature’s platform, your organization gains visibility among leading researchers while supporting potentially transformative medical innovation.
About Biopharma Dealmakers
Providing timely information on dealmaking activity, Biopharma Dealmakers brings together life scientists, biotech and pharmaceutical professionals and investors. Organizations seeking partners from the biopharma and investment community are invited to advertise and publish profile articles.
The publication is free to access at Nature.com/biopharmdeal and print issues are distributed to the readers of Nature Biotechnology and Nature Reviews Drug Discovery.
